



## Shagufta Shaheen

Clinical Assistant Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Rm 2238

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000      **Fax** (650) 723-8748

### Bio

---

#### BIO

Dr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

#### CLINICAL FOCUS

- Medical Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

#### PROFESSIONAL EDUCATION

- Fellowship: Stanford Hospital and Clinics Neuro-Oncology Fellowship CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Fellowship: Loma Linda University Hematology and Medical Oncology Fellowship (2018) CA
- Residency: St Joseph Hospital Internal Medicine Residency (2010) IL
- Medical Education: MGM Medical College (2004) India
- Fellowship, Stanford University , Neuroendocrine Tumor Fellowship (2019)
- Fellowship, Loma Linda University , Hematology and Oncology Fellowship (2018)

- Residency, Saint Joseph University of Illinois at Chicago , Internal Medicine (2010)
- Internship, Government Medical College, Kashmir , Internship (2003)
- Medical Education, MGM Medical College, India , Bachelor of Medicine and Surgery (2002)
- Board Certification, American Board of Internal Medicine , Medical Oncology (2018)
- Board Certification, American Board of Internal Medicine , Internal Medicine (2010)

## Research & Scholarship

---

### CLINICAL TRIALS

- A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours, Not Recruiting
- A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors, Not Recruiting
- Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors, Not Recruiting
- Chromogranin A as Blood Marker in Cancer Patients, Not Recruiting
- Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery, Not Recruiting
- Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors, Not Recruiting
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome, Not Recruiting
- Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors, Not Recruiting
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors, Not Recruiting

## Publications

---

### PUBLICATIONS

- **[177Lu]Lu-dota-tate radioligand therapy for advanced pancreatic neuroendocrine tumours.** *The Lancet. Oncology*  
Halfdanarson, T. R., Shaheen, S.  
2026; 27 (6): 652-653
- **Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Biomarker analysis results from a phase 2, randomized, parallel-group study.**  
Oviedo Albor, A., Mohamed, A., Riechelmann, R., O'connor, J., Maluccio, M., Singh, S., Hajac, L., Demeure, M. J., Dillon, J. S., Shaheen, S., Althoff, J., Dioca, M., Halfdanarson, et al  
LIPPINCOTT WILLIAMS & WILKINS.2026: 632
- **Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy.** *Breast cancer research and treatment*  
Hammer, P. M., Enamandram, S., Ikeda, D. M., Lam, M. M., Wapnir, I. L., Chamberlain, E. D., Shaheen, S., Caswell-Jin, J. L., Itakura, H., Bean, G. R.  
2025; 215 (1): 10
- **Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.** *Endocrine pathology*  
de Mestier, L., Halfdanarson, T. R., Apostolidis, L., Koumariannou, A., Hernando, J., Riechelmann, R., Bergsland, E. K., Cingarlini, S., Shaheen, S., Crona, J., Kreutzfeldt, S., Mosalem, O., Al-Toubah, et al  
2025; 36 (1): 42
- **First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [225Ac]Ac-DOTA-LM3.** *Clinical nuclear medicine*  
Perrone, E., Shaheen, S., Kunz, P. L., Henri, H. C., Baum, R. P.  
2025
- **Health-related quality of life (HRQOL) in the phase 3 trial of cabozantinib vs placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET, Alliance A021602).**

- Dueck, A. C., Fruth, B., Geyer, S., Zemla, T., Pulsipher, S., Ou, F., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T., Konda, B., Trikalinos, N., Shaheen, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 4020
- **Carcinoid heart disease and urinary 5-HIAA in patients with pancreatic neuroendocrine tumors.**  
Paranjpe, I., Hornbacker, K., Vadde, S., Shaheen, S.  
LIPPINCOTT WILLIAMS & WILKINS.2025: e16350
  - **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX): Two-Year primary outcome analysis.** *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology*  
Klebaner, D., Brown, E., Fisher, G. A., Shelton, A., Johnson, T. P., Shaheen, S., Chen, C., Heestand, G., Holden, T., Bien, J., King, D. A., Dawes, A. J., Morris, et al  
2025; 207: 110884
  - **Efficacy and safety of cabozantinib for advanced gastrointestinal (GI) neuroendocrine tumors (NET) after progression on prior therapy: Subgroup analysis of the phase 3 CABINET trial (Alliance A021602).**  
Strosberg, J. R., Zemla, T. J., Geyer, S., Knopp, M. V., Behr, S., Pulsipher, S., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T., Konda, B., Trikalinos, N., Tawfik, et al  
LIPPINCOTT WILLIAMS & WILKINS.2025: 666
  - **Circulating Chromogranin A as Surveillance Biomarker in Patients with Carcinoids - The CASPAR Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Meng, Q. H., Halfdanarson, T. R., Bornhorst, J. A., Jann, H., Shaheen, S., Shi, R. Z., Schwabe, A., Stadel, K., Halperin, D. M.  
2024
  - **Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors.** *The New England journal of medicine*  
Chan, J. A., Geyer, S., Zemla, T., Knopp, M. V., Behr, S., Pulsipher, S., Ou, F., Dueck, A. C., Acoba, J., Shergill, A., Wolin, E. M., Halfdanarson, T. R., Konda, et al  
2024
  - **Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX).**  
Pollom, E. L., Fisher, G. A., Shelton, A., Johnson, T., Chen, C., Jackson, S., Shaheen, S., Holden, T., Bien, J., King, D., Morris, A. M., Kin, C., Dawes, et al  
LIPPINCOTT WILLIAMS & WILKINS.2024
  - **Chromogranin A as surveillance biomarker in patients with carcinoids: CASPAR**  
Meng, Q., Halfdanarson, T., Bornhorst, J., Jann, H., Shaheen, S., Shi, R., Halperin, D. M.  
LIPPINCOTT WILLIAMS & WILKINS.2023
  - **Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177Lu-DOTATATE.** *Clinical nuclear medicine*  
Somoza, E. A., Duan, H., Shaheen, S., Fischer, G. A., Aparici, C. M.  
2022
  - **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.** *The oncologist*  
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., Mari Aparici, C.  
2022
  - **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up** *ONCOLOGIST*  
Duan, H., Ferri, V., Fisher, G., Shaheen, S., Davidzon, G., Iagaru, A., Aparici, C.  
2022
  - **Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience**  
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., Nguyen, J., Franc, B. L., Iagaru, A., Aparici, C.  
LIPPINCOTT WILLIAMS & WILKINS.2022: E42-E43
  - **Phase II trial of organ preservation program using short-course radiation and folfoxiri for rectal cancer (SHORT-FOX)**  
Pollom, E. L., Shelton, A., Fisher, G. A., Bien, J., King, D., Johnson, T., Chen, C., Shaheen, S., Chong, C., Vitzthum, L., Kirilcuk, N., Morris, A. M., Kin, et al

LIPPINCOTT WILLIAMS & WILKINS.2022

- **Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., Giordano, T., Halfdanarson, T. R., Halperin, et al  
2021; 19 (7): 839-868
- **Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan**  
Shaheen, S., Gardner, R., Sundaram, V., Hornbacker, K., Moradi, F., Wu, J., Kunz, P.  
LIPPINCOTT WILLIAMS & WILKINS.2020: 486
- **Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.** *Current treatment options in oncology*  
Shaheen, S. n., Moradi, F. n., Gamino, G. n., Kunz, P. L.  
2020; 21 (4): 25
- **Targeted and novel therapy in advanced gastric cancer** *EXPERIMENTAL HEMATOLOGY & ONCOLOGY*  
Selim, J. H., Shaheen, S., Sheu, W., Hsueh, C.  
2019; 8 (1): 25
- **Concomitant KRAS and BRAF mutations in colorectal cancer** *JOURNAL OF GASTROINTESTINAL ONCOLOGY*  
Midthun, L., Shaheen, S., Deisch, J., Senthil, M., Tsai, J., Hsueh, C.  
2019; 10 (3): 577-81
- **Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature.** *Experimental hematology & oncology*  
Shaheen, S., Mirshahidi, H., Nagaraj, G., Hsueh, C. T.  
2018; 7: 11
- **Characterization of disease progression in ovarian cancer by utilizing 'chemograms' of ovarian cancer stem cells.** *Journal of chemotherapy (Florence, Italy)*  
Guddati, A. K., Shaheen, S.  
2013; 25 (3): 184-91
- **Secondary mucosa-associated lymphoid tissue (MALT) lymphoma of the colon.** *Medical oncology (Northwood, London, England)*  
Shaheen, S., Guddati, A. K.  
2013; 30 (2): 502
- **Gastrointestinal stromal tumor: a rare abdominal tumor.** *Case reports in oncology*  
Shaheen, S., Guddati, A. K.  
2013; 6 (1): 148-53
- **Uterine leiomyosarcoma manifesting as a tricuspid valve mass.** *Case reports in oncology*  
Marak, C. P., Ponea, A. M., Alappan, N., Shaheen, S., Guddati, A. K.  
2013; 6 (1): 119-26
- **Extracavitary manifestation of primary effusion lymphoma as a right atrial mass.** *Case reports in oncology*  
Marak, C. P., Ponea, A. M., Shim, C., Shaheen, S., Guddati, A. K.  
2013; 6 (1): 114-8
- **Cutaneous metastasis of uterine adenocarcinoma: a case report and review of the literature.** *Cutis*  
Selim, A. A., Shaheen, S., Lockshin, N., Khachemoune, A.  
2009; 84 (1): 33-8
- **Melanotic neuroectodermal tumor of infancy: review of literature and case report.** *Journal of pediatric surgery*  
Selim, H., Shaheen, S., Barakat, K., Selim, A. A.  
2008; 43 (6): E25-9